Article Text

Download PDFPDF
Gastric adenocarcinoma: the role of Helicobacter pylori in pathogenesis and prevention efforts
  1. Heather S Laird-Fick1,2,
  2. Shivani Saini1,
  3. James Randolph Hillard3
  1. 1Department of Medicine, Michigan State University, East Lansing, Michigan, USA
  2. 2Department of Medicine, EW Sparrow Hospital, Lansing, Michigan, USA
  3. 3Department of Psychiatry, Michigan State University, East Lansing, Michigan, USA
  1. Correspondence to Dr Heather S Laird-Fick, Department of Medicine, Michigan State University, 788 Clinical Center B307, East Lansing, MI 48824, USA; heather.lairdfick{at}


Gastric cancer is the third most common cause of cancer deaths in the world, prompting high-risk countries like South Korea and Japan to establish nationwide screening programmes. Helicobacter pylori is linked to the majority of gastric adenocarcinoma cases and to the vast majority of non-cardia gastric adenocarcinomas. Several studies have demonstrated the effectiveness of ‘test-and-treat’ programmes for H. pylori infection to prevent gastric cancer in high-risk populations. While this strategy has gained momentum, providers in low-risk developed countries may be unaware of the risk individual patients face, particularly those who have emigrated from high-risk regions and members of economically disadvantaged minority groups. Rapidly evolving science in recent years has made it difficult for clinicians to keep up with the current best practices. This article reviews the epidemiology of H. pylori and gastric cancer, screening and diagnostic tests and the current treatment regimens for clinicians.


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.